Alembic Pharmaceuticals Limited (NSE:APLLTD)
India · Delayed Price · Currency is INR | Market Cap | 160.25B -9.6% |
| Revenue (ttm) | 77.84B +14.1% |
| Net Income | 6.93B +15.0% |
| EPS | 35.28 +14.9% |
| Shares Out | 196.56M |
| PE Ratio | 23.11 |
| Forward PE | 20.34 |
| Dividend | 12.00 (1.47%) |
| Ex-Dividend Date | Jul 29, 2026 |
| Volume | 327,523 |
| Open | 816.00 |
| Previous Close | 825.45 |
| Day's Range | 803.50 - 827.85 |
| 52-Week Range | 635.80 - 998.00 |
| Beta | 0.31 |
| Analysts | Buy |
| Price Target | 952.80 (+16.34%) |
| Est. Earnings | Nov 6, 2026 |
About Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspe... [Read more]
Financial Performance
In fiscal year 2026, Alembic Pharmaceuticals's revenue was 73.45 billion, an increase of 10.08% compared to the previous year's 66.72 billion. Earnings were 6.75 billion, an increase of 15.66%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for APLLTD stock is "Buy." The 12-month stock price target is ₹952.80, which is an increase of 16.34% from the latest price.
News
Alembic Pharmaceuticals Transcript: Q1 26/27
Q1 FY 2027 delivered 26% revenue growth, led by strong U.S. generics and robust animal health and API segments. EBITDA margin held at 16% despite continued R&D and branded platform investments. Growth outlook for FY 2027 is upgraded to mid-teens, with margin improvement expected as branded business scales.
Alembic Pharmaceuticals Quarterly report: Q1 2027
Alembic Pharmaceuticals has published its Q1 2027 quarterly earnings report on August 4, 2026.
Alembic Pharmaceuticals Slides: Q1 2027
Alembic Pharmaceuticals has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 4, 2026.
Pharma sector stocks today, July 2: Alembic Pharma falls 1.88%, Glenmark Pharma jumps 0.91%, Sun Pharma gains 0.67%
Indian pharma stocks showed mixed performance in early trading on July 2, 2026. The BSE Healthcare index rose 0.24% to 49,237.19, while the broader market also posted gains with the…
Top stocks for trade today June 29: Persistent Systems, Alembic Pharma, Lupin, Adani Green, BEML and more
Indian stock markets are expected to keep several companies in focus on June 29 following corporate announcements, regulatory approvals, project wins, acquisitions, fundraising plans, and operational ...
Alembic Pharmaceuticals receives USFDA final approval for Dapsone Gel, 5%
Alembic Pharmaceuticals Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dapsone Gel, 5%.…
Alembic Pharmaceuticals receives USFDA approval for Oseltamivir Phosphate
Alembic Pharmaceuticals Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oseltamivir Phospha...
Alembic Pharmaceuticals receives USFDA tentative approval for Binimetinib Tablets, 45 mg
Alembic Pharmaceuticals Limited has announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Binimetinib Tab...
Alembic Pharmaceuticals receives USFDA approval for Tretinoin Cream with market size of US$ 76 million
Alembic Pharmaceuticals Limited has secured final approval from the US Food & Drug Administration (USFDA) for its Tretinoin Cream USP, 0.05%. This approval is for the company's Abbreviated New Drug…
Alembic Pharmaceuticals receives USFDA tentative approval for Larotrectinib capsules
Alembic Pharmaceuticals Limited has announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib C...
Pharma sector stocks today, June 10: Panacea Biotech falls 8.09%, Wockhardt declines 1.47%, Alembic Pharma up 1.02%
Pharma stocks traded mixed on June 10, 2026, during the early morning session, with gains and losses spread across the sector. The broader market was positive, with the Nifty 50…
Alembic Pharma to acquire 45% stake in Canadian venture to expand pharmaceutical presence in canada
Alembic Pharmaceuticals Limited has announced the execution of a Shareholders' Agreement to invest in a newly incorporated Canadian corporation, marking a strategic step toward expanding its presence ...
Alembic Pharmaceuticals urges shareholders to update KYC details to avoid dividend withholding
Alembic Pharmaceuticals has issued a reminder to its shareholders holding shares in physical form to update their KYC details in compliance with a SEBI Master Circular. The company emphasised that…
Alembic Pharmaceuticals receives USFDA approval for Haloperidol Tablets
Alembic Pharmaceuticals Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Haloperidol Tablets...
Pharma sector stocks today, June 3: Natco Pharma falls 2.57%, Zydus Lifesciences falls 1.26%, Alembic Pharma down 1.06%
Pharmaceutical stocks traded mixed on June 3, 2026, during the morning session. While a few stocks posted modest gains, several others witnessed selling pressure. The BSE Healthcare index declined 0.2...
Alembic Pharmaceuticals gets USFDA nod for thyroid treatment tablets
Alembic Pharmaceuticals Ltd on Friday announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sod...
Pharma sector stocks today, May 22: Aurobindo Pharma falls 4.11%, Zydus Lifesciences rises 0.92%, Alembic Pharma up 1.06%
Pharmaceutical stocks traded mixed on May 22, 2026, during the morning session. While some stocks posted modest gains, a few names, including Aurobindo Pharma, witnessed sharp declines. The BSE Health...
Alembic Pharmaceuticals shares fall 8% on May 18 as Q4FY26 PAT misses estimates by 43% and Motilal Oswal cuts FY27 earnings by 12%
Shares of Alembic Pharmaceuticals Limited fell 8.02% to ₹721.25 on the NSE on May 18, 2026, shedding ₹62.85 from a previous close of ₹784.10, after the company's Q4FY26 results missed…
Pharma sector stocks fall today, May 18: Alembic Pharma crashes 8.32%, Natco Pharma down 2.48%, Aarti Drugs declines 2.27%
Indian pharmaceutical stocks traded mostly lower on May 18 2026 during the morning session. The BSE Healthcare index declined 0.87% to 46,781.22, in line with the broader market weakness. The…
Alembic Pharmaceuticals passes ANVISA GMP inspection at Karakhadi facility
Alembic Pharmaceuticals has successfully completed the Good Manufacturing Practice (GMP) inspection conducted by the Brazilian Health Regulatory Agency (ANVISA) at its API-III facility in Karakhadi. T...
Alembic Pharmaceuticals Transcript: Q4 25/26
FY 2026 delivered steady growth with 10% revenue and 16% profit increase, despite margin drag from the US branded launch. FY 2027 targets low double-digit growth, margin improvement, and continued R&D investment, with India and international segments expected to accelerate.
Alembic Pharmaceuticals Quarterly report: Q4 2026
Alembic Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 15, 2026.
Alembic Pharmaceuticals Slides: Q4 2026
Alembic Pharmaceuticals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 15, 2026.
Alembic Pharmaceuticals Annual report: Q4 2026
Alembic Pharmaceuticals has published its Q4 2026 annual report on May 15, 2026.
Alembic Pharmaceuticals reports 29% rise in Q4 net profit for FY26
Alembic Pharmaceuticals Limited has announced a strong financial performance for the fourth quarter of the fiscal year 2026, with a notable increase in both revenue and net profit. The company…